MGMaría Victoria García-Ortiz

María Victoria García-Ortiz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


María Victoria García-Ortiz has a total of 125 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    NR3C1 , LAX1 , and RCAN3 as Circulating Epigenetic Biomarkers for Prognosis and Chemotherapy Response Prediction in Metastatic Pancreatic Cancer

    by Pablo Cano‐Ramírez, Marta Toledano‐Fonseca, María Teresa Cano‐Osuna, Nerea Herrera‐Casanova, Emilio Carrillo‐Pecero, Antonio Rodríguez‐Ariza, Enrique Aranda, María Victoria García‐Ortiz

    Pancreatic cancer remains highly lethal, largely due to late diagnosis and limited efficacy of treatments. Improving first‐line treatment selection and patient monitoring requires novel, non‐invasive biomarkers beyond carbohydrate antigen 19‐9 (CA19‐9) and imaging. This study investigates epigenetic biomarkers from liquid biopsy with prognostic and predictive potential in metastatic pancreatic ductal adenocarcinoma (PDAC; mPDAC). Genome‐wide methylation profiling of cell‐free DNA (cfDNA) from healthy individuals and stage IV mPDAC patients identified 13 gene‐associated CpG sites with significantly altered methylation patterns. ddPCR validation confirmed consistent methylation differences in lymphocyte transmembrane adaptor 1 ( LAX1 ), nuclear receptor subfamily 3 group C member 1 ( NR3C1 ), and RCAN3 between healthy and patient groups. Elevated LAX1 and RCAN3 methylation and reduced NR3C1 methylation at diagnosis were associated with poor prognosis and correlated with high‐risk circulating biomarker profiles, including CA19‐9 levels, RAS MAF (mutant allele fraction), cfDNA concentration, and cfDNA fragmentation. Notably, baseline NR3C1 methylation levels predicted response to first‐line FOLFIRINOX‐based treatment with an acceptable 75% sensitivity and a high specificity of 92.86%. These findings highlight the clinical significance of cfDNA methylation as a minimally invasive biomarker source, emphasizing LAX1 , NR3C1 , and RCAN3 as prognostic biomarkers in mPDAC. Specifically, baseline NR3C1 methylation emerges as a promising predictor of treatment response, supporting personalized therapeutic strategies in mPDAC.

  • Open Access

    Glycolysis Inhibition Restores Immune Sensitivity in GSNOR–Deficient Colorectal Cancer

    by Ana Mantrana, María Teresa Sánchez-Montero, Carmen Navarrete-Sirvent, Nerea Herrera-Casanova, Rafael Mena-Osuna, Aurora Rivas-Crespo, Alejandra Díaz-Chacón, Virginia Ávila-Oca, Marta Toledano-Fonseca, María Victoria García-Ortíz, et al.


  • Open Access

    Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects

    by María Victoria García-Ortiz, Pablo Cano-Ramírez, Marta Toledano-Fonseca, Enrique Aranda, Antonio Rodríguez-Ariza

    Pancreatic cancer is one of the most challenging cancers due to its high mortality rates. Considering the late diagnosis and the limited survival benefit with current treatment options, it becomes imperative to optimize early detection, prognosis and prediction of treatment response. To address these challenges, significant research efforts have been undertaken in recent years to develop liquid-biopsy-based biomarkers for pancreatic cancer. In particular, an increasing number of studies point to cell-free DNA (cfDNA) methylation analysis as a promising non-invasive approach for the discovery and validation of epigenetic biomarkers with diagnostic or prognostic potential. In this review we provide an update on recent advancements in the field of cfDNA methylation analysis in pancreatic cancer. We discuss the relevance of DNA methylation in the context of pancreatic cancer, recent cfDNA methylation research, its clinical utility, and future directions for integrating cfDNA methylation analysis into routine clinical practice.


  • Open Access

    Clinical significance of glycogen synthase kinase 3 (GSK-3) expression and tumor budding grade in colorectal cancer: Implications for targeted therapy

    by Silvia Guil-Luna, Aurora Rivas-Crespo, Carmen Navarrete-Sirvent, Ana Mantrana, Alejandra Pera, Rafael Mena-Osuna, Marta Toledano-Fonseca, María Victoria García-Ortíz, Carlos Villar, Maria Teresa Sánchez-Montero, et al.


  • Open Access

    Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer

    by María Victoria García-Ortiz, Pablo Cano-Ramírez, Marta Toledano-Fonseca, María Teresa Cano, Elizabeth Inga-Saavedra, Rosa María Rodríguez-Alonso, Silvia Guil-Luna, María Auxiliadora Gómez-España, Antonio Rodríguez-Ariza, Enrique Aranda

    Background: Pancreatic cancer is the most lethal cancer with a dismal prognosis mainly due to diagnosis at advanced stage and ineffective treatments. CA19-9 levels and computed tomography (CT) imaging are the main standard criteria for evaluating disease progression and treatment response. In this study we explored liquid biopsy-based epigenetic biomarkers for prognosis and monitoring disease in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Methods: Plasma samples were collected from 44 mPDAC patients at the time of diagnosis, and in 15 of them, additional samples were obtained during follow-up of the disease. After cell-free DNA (cfDNA), isolation circulating levels of methylated NPTX2, SPARC, BMP3, SFRP1 and TFPI2 genes were measured using digital droplet PCR (ddPCR). BEAMing technique was performed for quantitation of RAS mutations in cfDNA, and CA19-9 was measured using standard techniques. Results: NPTX2 was the most highly and frequently methylated gene in cfDNA samples from mPDAC patients. Higher circulating NPTX2 methylation levels at diagnosis were associated with poor prognosis and efficiently stratified patients for prediction of overall survival (6.06% cut-off, p = 0.0067). Dynamics of circulating NPTX2 methylation levels correlated with disease progression and response to therapy and predicted better than CA19-9 the evolution of disease in mPDAC patients. Remarkably, in many cases the disease progression detected by CT scan was anticipated by an increase in circulating NPTX2 methylation levels. Conclusions: Our study supports circulating NPTX2 methylation levels as a promising liquid biopsy-based clinical tool for non-invasive prognosis, monitoring disease evolution and response to treatment in mPDAC patients.


  • Open Access

    A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

    by M. Toledano-Fonseca, M.A. Gómez-España, E. Élez, C. Grávalos, P. García-Alfonso, R. Rodríguez, F. Losa, I. Alés Díaz, B. Graña, M. Valladares-Ayerbes, et al.


  • Open Access

    The Combination of Neutrophil–Lymphocyte Ratio and Platelet–Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreatic Cancer

    by Marta Toledano-Fonseca, M. Teresa Cano, Elizabeth Inga, Auxiliadora Gómez-España, Silvia Guil-Luna, María Victoria García-Ortiz, Rafael Mena-Osuna, Juan R. De la Haba-Rodriguez, Antonio Rodríguez-Ariza, Enrique Aranda

    Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a highly inflammatory microenvironment and liquid biopsy has emerged as a promising tool for the noninvasive analysis of this tumor. In this study, plasma was obtained from 58 metastatic PDAC patients, and neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), circulating cell-free DNA (cfDNA) concentration, and circulating RAS mutation were determined. We found that NLR was significantly associated with both overall survival (OS) and progression-free survival. Remarkably, NLR was an independent risk factor for poor OS. Moreover, NLR and PLR positively correlated, and combination of both inflammatory markers significantly improved the prognostic stratification of metastatic PDAC patients. NLR also showed a positive correlation with cfDNA levels and RAS mutant allelic fraction (MAF). Besides, we found that neutrophil activation contributed to cfDNA content in the plasma of metastatic PDAC patients. Finally, a multi-parameter prognosis model was designed by combining NLR, PLR, cfDNA levels, RAS mutation, RAS MAF, and CA19-9, which performs as a promising tool to predict the prognosis of metastatic PDAC patients. In conclusion, our study supports the idea that the use of systemic inflammatory markers along with circulating tumor-specific markers may constitute a valuable tool for the clinical management of metastatic PDAC patients.


  • Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes

    by Carmen Martínez-Losada, Juana Serrano-López, Josefina Serrano-López, Nelida I. Noguera, Eduardo Garza, Liliana Piredda, Serena Lavorgna, María Antonietta Irno Consalvo, Tiziana Ottone, Valentina Alfonso, et al.

    Acute myeloid leukemia (AML) is a dynamic disease caused by accumulating, somatically acquired driver mutations generating branching competing clones.[1][1] In favorable-risk AML, high resolution genomic profiling by single nucleotide polymorphism array analysis of paired diagnostic-relapse NPM1 mut


  • DNA methylation reprogramming of human cancer cells by expression of a plant 5-methylcytosine DNA glycosylase

    by Teresa Morales-Ruiz, María Victoria García-Ortiz, Iván Devesa-Guerra, Laura Raya-Ruiz, Juan R. Tejedor, Gustavo F. Bayón, Marta I. Sierra, Mario F. Fraga, Rafael R. Ariza, Teresa Roldán-Arjona

    Patterns of DNA methylation, an important epigenetic modification involved in gene silencing and development, are disrupted in cancer cells. Understanding the functional significance of aberrant methylation in tumors remains challenging, due in part to the lack of suitable tools to actively modify methylation patterns. DNA demethylation caused by mammalian DNA methyltransferase inhibitors is transient and replication-dependent, whereas that induced by TET enzymes involves oxidized 5mC derivatives that perform poorly understood regulatory functions. Unlike animals, plants possess enzymes that directly excise unoxidized 5mC from DNA, allowing restoration of unmethylated C through base excision repair. Here, we show that expression of Arabidopsis 5mC DNA glycosylase DEMETER (DME) in colon cancer cells demethylates and reactivates hypermethylated silenced loci. Interestingly, DME expression causes genome-wide changes that include both DNA methylation losses and gains, and partially restores the methylation pattern observed in normal tissue. Furthermore, such methylome reprogramming is accompanied by altered cell cycle responses and increased sensibility to anti-tumor drugs, decreased ability to form colonospheres, and tumor growth impairment in vivo. Our study shows that it is possible to reprogram a human cancer DNA methylome by expression of a plant DNA demethylase.


  • Pre-clinical and in vitro epigenetic studies on the genome-wide impact of high-consuming beverages

    by Rocio Merinas-Amo, Marcos Mateo-Fernandez, Rocio Ruiz-Calzado, Maria Martinez-Jurado, Gabriel Anaya, Teresa Morales-Ruiz, Mª Victoria Garcia-Ortiz, Alberto Membrillo, Angeles Alonso-Moraga, Tania Merinas-Amo